Breakthrough T1D Blog

Novel dual-hormone artificial pancreas offers hope for better management of T1D

Drs. Ahmad Haidar, Laurent Legault, Michael Tsoukas and Jean-Franҫois Yale are a team of JDRF-funded researchers at McGill University (Montreal) who are the first to test the addition of pramlintide (a synthetic form of amylin, which is a hormone co-secreted with insulin by the healthy pancreas) to an artificial pancreas system – a combined treatment they hypothesize would help patients achieve optimal glucose control during the day.

A Look into the 2020 Pre-Budget Consultations

JDRF President and CEO Dave Prowten testified recently in front of the Standing Committee on Finance as part of their 2020 Pre-Budget Consultations. Also appearing on JDRF’s behalf was Angie Sullivan, parent of a child with type 1 diabetes (T1D).

JDRF celebrates top 10 advances in research

Now that 2019 has drawn to a close, we want to take a moment and extend our sincere thanks and appreciation for your support of our efforts in finding cures for type 1 diabetes (T1D) and improving the lives of the more than 300,000 Canadians and their families touched by this disease.

Sign up for our newsletter and stay connected

Receive the latest news and updates from Breakthrough T1D Canada

Help us create a world without type 1 diabetes

Give Now